Logo

German Congress of Orthopaedics and Traumatology 2026 (DKOU 2026)

Deutsche Gesellschaft für Orthopädie und Unfallchirurgie (DGOU), Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC), Deutsche Gesellschaft für Unfallchirurgie (DGU), Berufsverband für Orthopädie und Unfallchirurgie (BVOU)
20.-23.10.2026
Berlin

Meeting Abstract

Autologous chondrocyte implantation with spheroids of human autologous matrix-associated chondrocytes for femoroacetabular cam impingement-related acetabular cartilage defects yields similar clinical but superior radiological outcomes compared with bone marrow-stimulated debridement

Moses Kamal Dieter El Kayali - Charité – Universitätsmedizin Berlin, Berlin, Deutschland
Goumenos Stavros - Charité – Universitätsmedizin Berlin, Berlin, Deutschland
Pidgaiska Olga - Charité – Universitätsmedizin Berlin, Berlin, Deutschland
Ulrich Stöckle - Charité – Universitätsmedizin Berlin, Berlin, Deutschland
Alp Paksoy - Charité – Universitätsmedizin Berlin, Berlin, Deutschland
Sebastian Meller - Charité – Universitätsmedizin Berlin, Berlin, Deutschland

Text

Objectives and questions: Autologous chondrocyte implantation (ACI) using spheroids of human autologous matrix-associated chondrocytes is an established treatment for focal cartilage defects, but evidence for its use in the hip remains limited. For CAM-type femoroacetabular impingement (CAM-FAI), acetabular cartilage lesions can also be managed with bone-marrow–stimulated debridement (BMSD). This study compared the clinical and radiological outcomes of ACI with chondrosphere implantation versus BMSD for the treatment of CAM-FAI–related acetabular cartilage defects.

Material and methods: This matched-pair study retrospectively identified adult patients treated with either ACI using spheroids of autologous matrix-associated chondrocytes (CO.DON AG) or BMSD for CAM-FAI–associated acetabular cartilage defects and prospectively evaluated them at a follow-up ≥2 years post-treatment. A 1:1 matched-pair design was applied using strict matching criteria. Clinical outcomes included iHOT-33, mHHS, HOOS, and VAS pain. Radiological outcomes were assessed by MRI using the MOCART score. Descriptive and matched-pair statistical analyses were performed.

Results: A total of 31 (5/31 females) matched patient pairs (62 patients) were included in the analysis. The mean age at treatment was 34 ± 10 years in the ACI group and 35 ± 12 years in the BMSD group, and the mean follow-up interval was 7.8 ± 1.8 and 8.2 ± 1.7 years, respectively. Mean defect size measured 5.1 ± 0.9 cm² in the ACI group and 4.2 ± 1.3 cm² in the BMSD group. iHOT-33, mHHS, HOOS, and VAS pain scores did not differ statistically between ACI and BMSD. MRI evaluation indicated superior cartilage repair quality after ACI. MOCART scores were 80 ± 15 for ACI and 50 ± 15 for BMSD (p < 0.001).

Discussion and conclusions: ACI and BMSD resulted in comparable clinical outcomes, but MRI findings indicated superior cartilage repair quality after ACI. These results suggest a potential structural advantage of ACI, warranting longitudinal studies to evaluate its impact on cartilage preservation and osteoarthritis progression.